4//SEC Filing
Yang Arvin 4
Accession 0001104659-22-124083
CIK 0001442836other
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 4:01 PM ET
Size
18.7 KB
Accession
0001104659-22-124083
Insider Transaction Report
Form 4
Yang Arvin
Chief Medical Officer
Transactions
- Sale
Common Stock
2022-12-01$6.59/sh−5,527$36,423→ 25,946 total - Exercise/Conversion
Common Stock
2022-11-30+18,500→ 31,473 total - Exercise/Conversion
Restricted stock unit
2022-11-30−18,500→ 0 total→ Common Stock (18,500 underlying)
Footnotes (5)
- [F1]Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on November 30, 2020.
- [F2]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $6.38 to $6.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F5]The restricted stock units vested in full November 30, 2022.
Issuer
Mersana Therapeutics, Inc.
CIK 0001442836
Entity typeother
Related Parties
1- filerCIK 0001834321
Filing Metadata
- Form type
- 4
- Filed
- Dec 1, 7:00 PM ET
- Accepted
- Dec 2, 4:01 PM ET
- Size
- 18.7 KB